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INTRODUCTION
Autoimmune  hep at i t i s 
(AIH) is an uncommon chronic 
inflammatory disease in which 
loss of immunotolerance against 
hepatic tissue is presumed. It 
is characterized by a female 
predominance, histological 
features of periportal hepatitis 
in the absence of viral markers, 
hyp ergammaglobul inemia 
and the presence of serum 
autoantibodies [1].
Diagnostic scoring systems 
have been developed that support 
the diagnosis in the majority of 
patients [2]. A simplified scoring 
system with four variables was 
recently developed that enhances 
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Background & Aims: In recent years chronic courses of hepatitis E virus (HEV) infection have been described 
in immunosuppressed individuals. This may implicate a potential role for HEV in the development of 
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antibodies in AIH patients in an endemic Central European country. 
Methods: HEV-specific immunoglobulin G (IgG) and HEV RNA were determined in 354 and 377 AIH 
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Results: No HEV viraemic patients were identified in this cohort. A total of 106 AIH patients (29.9%) tested 
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including 5,329 healthy Dutch blood donors (26.7%; P>0.05). 
Conclusion: This is the largest study on the association between HEV infection and AIH. Apparently silent 
HEV infection is present in a significant proportion of AIH patients, yet appears not to have significant clinical 
repercussions in this immune compromised group of patients. Nevertheless, since acute hepatitis E may 
present with histological and biochemical features of AIH, the possibility of a (concomitant) HEV infection 
should be considered in this category of patients. 
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applicability in daily practice. In this scoring system points 
were subtracted if viral hepatitis was present [3]. Genetic 
background, hormones and environmental agents are 
persistently listed as contributing factors to AIH development. 
Exogenous factors, such as viruses and drugs, have been 
proposed as triggers for AIH. There have been occasional cases 
presenting shortly after documented infection with hepatitis A 
virus [4, 5], cytomegalovirus [6], Epstein Barr virus (EBV) [7] 
and hepatitis E virus (HEV) [8, 9]. This supports the evidence 
of the initiating role of hepatitis viruses in the development of 
AIH and other autoimmune diseases [10].
Hepatitis E virus infection is an important cause of acute 
clinical hepatitis in adults throughout Asia, the Middle East 
and Africa. Recent data suggest that HEV could be more 
widespread than previously thought and that the disease 
can also be found in more developed countries. The course 
of HEV infection can vary substantially between different 
individuals. Although most infections follow a clinically 
silent asymptomatic course, other patients may develop 
severe hepatitis that can progress to fulminant hepatic failure 
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[11]. In recent years, a chronic course of HEV infection has 
been described in immunosuppressed individuals including 
AIH patients who are taking immunosuppressive drugs [12]. 
Studies on the prevalence of HEV in AIH patients are scarce 
and performed in small sample sets. A recent study by Pischke 
et al. involving 208 AIH patients found that AIH patients are 
more likely to test anti-HEV positive and it is recommended 
to rule out HEV infections, especially in AIH patients not 
responding to immunosuppressive treatment [13]. More 
clinical observations are required to reveal the possible link 
between HEV and AIH. 
Here we aimed to further investigate the potential 
association between HEV and AIH by assessing the prevalence 
of HEV RNA and HEV antibodies in a large cohort of Dutch 
AIH patients and controls.
PATIENTS AND METHODS
Patient population 
The AIH patients were identified by the Dutch AIH Study 
Group consortium (http://www.autoimmuunhepatitis.nl) 
involving the gastroenterology and hepatology departments 
from 6 academic and 19 general hospitals in the Netherlands 
and has been described in details elsewhere [14]. AIH patients 
were identified by their treating physicians and by searching 
the database for international classification of diseases (ICD) 
codes. The search was performed in local diagnostic registers 
in the departments of gastroenterology and hepatology as well 
as internal medicine. In all patients clinical and biochemical 
parameters were assessed to exclude other aetiologies such 
as alcohol, drugs and metabolic disorders. Viral hepatitis (B 
and C) was excluded by serological testing. If performed, liver 
biopsy was used to establish diagnosis and the presence of 
fibrosis and cirrhosis. We recorded manifestations of overlap 
syndromes with primary biliary cirrhosis (PBC) and primary 
sclerosing cholangitis (PSC) in the presence of AIH if available. 
For PBC, these criteria consisted of anti-mitochondrial 
antibody (AMA) titres higher than 1:80 and typical histological 
findings, whereas manifestations of PSC were recorded in cases 
of typical histological and radiological findings. Diagnostic 
scores were determined according to the revised original 
International Autoimmune Hepatitis Group (IAIHG) criteria 
[2]. Available data on induction and maintenance therapy, 
as initiated and recorded by the treating physician, were 
retrospectively collected from the patient hospital records. 
Similarly, both clinical response to induction therapy and 
the occurrence of a relapse after treatment withdrawal were 
scored as assessed by the treating physician. In the 6 academic 
centres when a liver transplantation had been performed and 
when a patient developed a hepatocellular carcinoma (HCC), 
it was documented. Prior to the start of the study, institutional 
review board approval to carry out the study was obtained in 
all participating centres. 
Control population
Findings were compared with a control group of healthy 
blood donors from a recent study on the prevalence of HEV 
in the Netherlands (n= 5,329) [15]. 
HEV RNA detection
From September 2010 until January 2011 serum samples 
were obtained from each subject. The samples were aliquoted 
and stored frozen at -80°C. HEV RNA was tested by an 
internally controlled quantitative real-time Polymerase Chain 
Reaction (RT-PCR,) as described elsewhere [16]. In one serum 
sample the volume was not sufficient to test for HEV RNA. The 
RT-PCR had a lower limit of detection (LOD, 95% cut-off) of 
143 IU/ml HEV RNA, as determined by the first World Health 
Organization (WHO) standard for HEV RNA nucleic acid 
testing-based assays (6329/10, Paul Ehrlich Institute, Germany) 
[17]. Due to the limited sample volume, samples were diluted 
10x prior to testing, thereby increasing the LOD to 1430 IU/ml.
HEV-specific antibody detection
In addition, the samples were collected to determine HEV 
IgG seroprevalence with subsequent testing for HEV-specific 
immunoglobulin G (IgG) in serum or EDTA plasma samples. 
In 23 serum samples the volume was not sufficient to test 
anti-HEV IgG. A commercially available enzyme-linked 
immunosorbent assay (ELISA; Wantai, Beijing, China) was 
used according to the manufacturer’s instructions. 
Patients tested positive (optical density, OD>1.1), 
intermediate (0.9 <OD>1.1) or negative (OD <0.9). In clinical 
practice when patients test intermediate, a control sample is 
done after two weeks to ensure positivity. Since no follow 
up sample was collected in this study, patients that tested 
intermediate were marked negative. 
Statistical analysis
Summary statistics for categorical variables are expressed as 
numbers (percentages). Quantitative variables are described as 
medians with their range if not normally distributed. Statistical 
analysis was performed using Statistical Package for Social 
Sciences (SPSS) version 20, IBM, corp, Armonk NY. Depending 
on the distribution, parametric and nonparametric tests 
including Mann Witney test were used to test for differences 
within and between groups. The chi square test was used for 
the comparison between the results of the recent study and 
controls (adapted from Slot et al.) [15]. A two sided P-value < 
0.05 was considered statistically significant. 
RESULTS
Cohort characteristics
The AIH cases consisted of 66 (17%) males and 311 (83%) 
females with a mean age at diagnosis of 45 years (SD±18). The 
median IAIHG diagnostic score was 18 (Interquartile range, 
IQR: 15-21) (18). Based on the antibody profile, the large 
majority (95%) had type 1 AIH, whereas a small minority 
had positive anti-LKM 1 antibodies and was thus classified 
as type 2 AIH. Evidence for a clinical overlap-syndrome with 
PBC (AIH-PBC) and PSC (AIH-PSC) was found in 23 (7%) 
patients and 13 (3%) patients, respectively. 
Prevalence of HEV RNA and HEV-specific antibodies
None of the 377 AIH patients tested positive for the 
presence of HEV RNA. In addition, patients were screened 
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for IgG antibodies against HEV. In 23 patients the serum or 
plasma volume were insufficient for this analysis. Five patients 
tested intermediate and as mentioned before were marked 
negative. Screening of 354 AIH patients for the presence of 
HEV antibodies revealed 106 patients who were positive for 
anti-HEV IgG, which represents a seroprevalence of 29.9%. 
This is slightly higher when compared to the prevalence of 
26.7% in the Dutch population [15]; however, this difference 
was not significant (P= 0.18). 
In both the general Dutch population as well as in the AIH 
patients, the anti-HEV IgG seroprevalence strongly increased 
with age (P=0.01). Subanalysis in age-adjusted groups (grouped 
in 10-year cohorts) did not reveal differences between AIH 
patients and the general population (Fig. 1). 
In the small group of 18-30 years AIH patients, the 
seroprevalence of anti-HEV IgG was 21.2% compared to 12.6% 
in the general population (difference not significant P= 0.12). 
Association of anti-HEV IgG with clinical features
Anti-HEV IgG positivity was associated with age of onset 
(median age 55 vs. 44 years) (P=0.01), but not with gender. 
Anti-HEV IgG was not associated with a higher IAIHG score 
at diagnosis. Median alanine aminotransferase (ALT) levels, 
IgG and alkaline phosphatase (ALP) levels at time of diagnosis 
were not associated with anti-HEV IgG. Antinuclear antibodies 
(ANA) and liver kidney microsomal antibodies (LKM-1) 
positivity was equally distributed among the anti-HEV IgG 
positive and negative patients. Smooth muscle antibodies 
(SMA) were associated with anti-HEV IgG (P=0.03). 
We could not identify a significant relationship between 
anti- HEV IgG and the occurrence of AIH-PSC and AIH-PBC. 
Anti-HEV IgG were not associated with cirrhosis and fibrosis. 
Patients with anti-HEV IgG did not receive medication more 
often and no association between anti-HEV IgG and response 
to treatment was found.  
Evidence of hepatocellular carcinoma (HCC) was observed 
in one patient who was anti-HEV IgG negative. A liver 
transplantation had not been performed in any of the patients. 
All characteristics are summarized in Table I. 
DISCUSSION
In this large multicentre study, we demonstrated that the 
prevalence of anti-HEV IgG in AIH patients is similar to that in 
age-matched healthy controls. In addition, we did not identify 
chronically HEV-infected patients that were erroneously 
classified as AIH. 
Reports on anti-HEV IgG seroprevalence in AIH patients 
date back to the 1990s [9, 19]. In 1997, Le Cann et al. studied 
the sera of 52 AIH patients in the United States; anti-HEV IgG 
Fig. 1. Anti-HEV IgG seroprevalence in the 10-year age groups of AIH 
patients and the general population in the Netherlands.
Table I. Patient characteristics in anti-HEV IgG positive and negative AIH patients at diagnosis
Features Anti-HEV IgG negative Anti-HEV IgG positive (N) P
N=248 N=106
Gender (female); n (%) 208 (83%) 88 (83%) 354 0.9
Median age; years  (IQR ) 44 (26-58) 54 (41-63) 354 0.01
Median ALT;  IU/L (IQR) 401 (179-901) 361 (199-900) 354 0.3
Median IgG;  g/L (IQR) 22.3 (16.2-31.3) 22.5 (18.1-29.2) 347 0.9
Median ALP; IU/L (IQR) 135 (94-203) 181 (121-255) 351 0.5
Median IAIHG score (IQR) 18 (15-21) 18 (16-21) 339 0.6
SMA positive; n (%) 95 (41%) 54 (54%) 332 0.03
ANA positive; n (%) 139 (60%) 56 (56%) 332 0.5
Cirrhosis/fibrosis (biopsy); n (%) 18/105 (10%/56%) 13/51 (15%/58%) 276 0.2/0.7
Concomitant autoimmune disease; n (%) 46 (20%) 22 (22%) 331 0.9
PBC overlap; n (%) 17 (7%) 7 (7%) 335 0.9
PSC overlap; n (%) 8 (3%) 3 (3%) 331 0.9
Portal hypertension; n (%) 5 (2%) 0 (0%) 354 0.3
HCC; n (%) 1 (0.4%) 0 (0%) 354 1
Liver transplantation and waiting list; n (%) 0 (0%) 0 (0%) 354 0.08
Mono/combination treatment; n (%) 90/100 (39%/43%) 45/40 (50%/44%) 331 0.4
IQR: Interquartile range; ALT: alanine aminotransferase; ALP: Alkaline phosphatase; AIHG: International autoimmune 
hepatitis group; SMA: smooth muscle antibodies; ANA: antinuclear antibodies; PBC: Primary biliary cirrhosis; PSC: Primary 
sclerosing cholangitis; HCC: Hepatocellular carcinoma.
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was found in 7 patients (13%). However, systematic large scale 
studies on the prevalence of HEV in AIH patients have not 
been reported so far. In addition, these studies were hampered 
by the fact that they were executed in single centre or tertiary 
referral hospitals. 
There is no gold standard for HEV antibody testing, which 
impairs the ability to compare different studies. In a recent 
study by Pischke et al. involving 208 German AIH patients, 
the seroprevalence of anti-HEV IgG was higher (7.7%) than 
in the healthy controls (2%) [12]. The MP/Genelabs assay 
used in this study was also employed in a recent study in 
7,072 Dutch samples collected in 2006 and 2007, in which a 
seroprevalence of only 2.6% was found [20]. When compared to 
the Wantai assay used in this study, the MP/Genelabs assay was 
shown to be considerably less sensitive in PCR-proven HEV 
cases which explains the considerable higher seroprevalence 
found in this study [21, 22]. In the study by Pischke et al., in a 
subgroup of AIH patients (n=123) anti-HEV was tested using 
the Wantai assay.  When using the Wantai assay 33% AIH 
patients tested anti-HEV positive, confirming the Wantai assay 
to be more sensitive [13]. In Austria, using the same assay a 
seroprevalence of 22.7% was found [23]. Other studies have 
shown that the seroprevalence among the general population 
varies widely. Thus, while using the same antibody assay 
(Wantai) as employed in this study, a seroprevalence of 16% 
was found in a cohort of healthy donors in the south-west of 
the United Kingdom (n=500) [24], whereas this percentage 
was as high as 53% in south-western France (n=512) [21]. Our 
findings presented in this study are in line with these earlier 
observations. In our study 29.9% AIH patients tested positive 
for anti-HEV using the Wantai assay. Although not significant, 
this is slightly higher when compared to the prevalence of 
26.7% in the general Dutch population [15]. Based on these 
results, an association between AIH and HEV cannot be 
confirmed, although due to the slightly higher prevalence in 
AIH patients it cannot be completely ruled out. 
As mentioned in earlier studies there is a striking age related 
seroprevalence, while HEV IgG positivity was associated with 
age of onset (median age 55 vs. 44 years). This may simply 
reflect a long-standing stable situation, in which people are 
evenly exposed to HEV in the course of their life. 
In the small group of AIH patients aged 18-30 years, the 
seroprevalence of anti-HEV IgG was 21.2% compared to 12.6% 
in the general population; this difference was not significant 
(perhaps due to the small size of this subgroup). One possible 
explanation for the elevated seroprevalence in young AIH 
patients is that previous HEV infection in some of these young 
patients might have triggered the later development of AIH. 
The current pathogenic concept of AIH is that a genetically 
susceptible subject is exposed to an environmental agent, 
which triggers an autoimmune process. Various viruses have 
been supposed to be the triggering agent of AIH, but for most 
of these no compelling evidence has been  found [5]. Some 
studies have suggested that EBV could trigger the process, 
whereas others have found evidence for suggested other viruses 
such as initiators of the disease [25]. 
A similar concept has been proposed for neurologic 
manifestations such as Guillain Barré syndrome and Neuralgic 
Amyotrophy in association with HEV infection [26, 27]. 
While based on the observations in this cross-sectional study, 
it cannot be ruled out completely that an HEV infection may 
have triggered immune events leading to the manifestation 
of AIH in a subset of patients; a role for a chronic persistent 
infection appears unlikely.  
Based on these results we cannot rule out that in younger 
AIH patients the HEV seroprevalence is higher compared to 
that of the general population; other studies are necessary to 
confirm this.  
Acute hepatitis E presents with histological and biochemical 
features of AIH and thus acute HEV infection may be 
misclassified as de novo onset of AIH and treatment with 
immunosuppressants in acutely infected patients may 
accelerate histological progression. Since HEV infection might 
be life threatening in immunocompromised patients [16] and 
most AIH patients will be treated with low doses of steroids 
with or without azathioprine, routine serological testing of 
HEV infection should be strongly recommended in the initial 
work-up of AIH. Similarly, AIH patients with unexplained 
elevated liver enzymes should also be tested for HEV-RNA.
CONCLUSION
No AIH patients with active HEV were found in our 
study and we did not identify chronically HEV-infected AIH 
patients. In addition, the seroprevalence of anti-HEV IgG, 
suggesting past exposure to HEV is almost similar in Dutch 
AIH patients to that in the general Dutch population. Despite 
the absence of active HEV disease, awareness of the possibility 
of HEV infection in patients diagnosed with AIH should be 
kept in mind. 
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